Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib plus R-CHOP in previously untreated non-GCB diffuse large B-cell lymphoma
CTR20212036Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of acalabrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by AstraZeneca. Started Nov 2021; status: active.
02
Drugs
acalabrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20212036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212036.